We are live on ! Find out more
ANIX icon

Anixa Biosciences
ANIX

18 hedge funds and large institutions have $3.25M invested in Anixa Biosciences in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more capital invested

Capital invested by funds: $2.23M → $3.25M (+$1.02M)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0% more funds holding

Funds holding: 18 → 18 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.63% less ownership

Funds ownership: 5.7% → 5.07% (-0.63%)

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$106K
2
VF
Virtu Financial
New York
+$101K
3
Northern Trust
Northern Trust
Illinois
+$62.5K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$4.73K
5
Morgan Stanley
Morgan Stanley
New York
+$3.18K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$611K
2
TSS
Two Sigma Securities
New York
-$28K
3
Bank of America
Bank of America
North Carolina
-$4K
4
UBS Group
UBS Group
Switzerland
-$2.86K
5
EWM
Evercore Wealth Management
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.2M -$611K -158,809 -22%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$336K – – –
Bank of New York Mellon
3
Bank of New York Mellon
New York
$178K +$4.73K +1,230 +3%
Northern Trust
4
Northern Trust
Illinois
$140K +$62.5K +16,248 +80%
Goldman Sachs
5
Goldman Sachs
New York
$106K +$106K +27,479 New
VF
6
Virtu Financial
New York
$101K +$101K +26,201 New
DIA
7
Denver Investment Advisors
Colorado
$67K – – –
CAM
8
Concorde Asset Management
Michigan
$53K – – –
UBS Group
9
UBS Group
Switzerland
$24K -$2.86K -744 -10%
BlackRock
10
BlackRock
New York
$19K – – –
Morgan Stanley
11
Morgan Stanley
New York
$7K +$3.18K +826 +78%
Wells Fargo
12
Wells Fargo
California
$4K – – –
Deutsche Bank
13
Deutsche Bank
Germany
$4K +$385 +100 +10%
JP Morgan Chase
14
JP Morgan Chase
New York
$3K – – –
TSS
15
Two Sigma Securities
New York
– -$28K -12,047 Closed
Bank of America
16
Bank of America
North Carolina
– -$4K -1,040 -93%
SWM
17
SeaCrest Wealth Management
New York
– -$1K -500 Closed
EWM
18
Evercore Wealth Management
New York
– -$1K -400 Closed
Barclays
19
Barclays
United Kingdom
– +$58 +15 New

ANIX Hedge Fund Activity: Q1 2018 in Review

18 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q1 2018, worth a combined $3.25M — up 46% from $2.23M a quarter earlier.

Fund positioning in ANIX was balanced in Q1 2018: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $106K. The largest seller was Vanguard Group, cutting an estimated $611K.

  • 18 institutional investors held Anixa Biosciences (ANIX) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $3.25M of Anixa Biosciences stock for Q1 2018, up 46% quarter-over-quarter.
  • 3 funds opened new Anixa Biosciences positions in Q1 2018 and 3 closed out, a net change of 0 holders.
  • The largest Anixa Biosciences buyer in Q1 2018 was Goldman Sachs, an estimated $106K added.
  • The largest Anixa Biosciences seller in Q1 2018 was Vanguard Group, an estimated $611K sold.

Based on aggregated 13F filings for Q1 2018.